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Abstract  
Introduction: Considering that hemorrhagic stroke patients are at higher risk for bleeding, administration of 
higher doses of melatonin with a controversial coagulation profile is a serious concern.  
Objective: This study aimed to investigate the possible effects of high doses of melatonin on bleeding 
parameters and blood hemostasis in hemorrhagic stroke patients. 
Methods: This study is a randomized, double-blind, prospective, controlled trial. Confirmed hemorrhagic 
stroke patients were divided into two groups. Participants were randomly assigned into the melatonin group 
(30 mg daily via gastric tube gavage for 5 consecutive days) or the control group. Each patient was monitored 
for 5 days, and 2 blood samples were taken and the effect of the intervention on coagulation factors and blood 
hemostasis were investigated. 
Result: In total, 30 patients were randomly assigned to melatonin (n=15) or control groups (n=15). there 
was no significant difference between the two groups in demographic and clinical characteristics. There was 
a significant decline in prothrombin time (PT) and fibrinogen levels in the melatonin group (p=0.011 & 
p<0.001, respectively). P-values for VII and VWB factors showed a significant increment in these two factors 
in the melatonin group after the intervention (p=0.035 & p=0.002, respectively). No significant changes in 
serum levels of D-dimer factor, APACHE II, and GCS scores were evident in the two groups after the 
intervention (p>0.05).  
Conclusion: Considering the favorable changes in coagulation parameters observed in this study, it could be 
concluded that melatonin can have both procoagulant and antithrombin properties. 
Key words: Blood Coagulation Disorders; Factor VII; Fibrinogen; Hemorrhagic Stroke; Melatonin; von 
Willebrand Factor 
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INTRODUCTION
Hemorrhagic stroke is a dominant cause of 
disability and even death worldwide (1). Notably, 
various molecular and cellular events such as 
inflammation, apoptosis, and oxidative stress are 
involved in hemorrhagic stroke's pathogenesis (2). 
Melatonin has been proven to have 
neuroprotective properties against brain injury in 
hemorrhagic stroke via multiple molecular 
mechanisms. This is assumed due to its 
antioxidant, anti-inflammatory, and anti-apoptosis 
properties (3). Melatonin is a broad-spectrum 
neuro-hormone and a potent free radical 
scavenger. It is centrally synthesized by the pineal 
gland and directly released into the blood (3, 4). 
This neuro-hormone is a ubiquitous agent in 
almost every living organism, from bacteria and 
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viruses to vertebrates (5).  In the human body, the 
hypothalamic suprachiasmatic nucleus controls 
the synthesis and release of this substance.  
There is evidence suggesting that melatonin, as an 
antithrombotic agent, can cause decrement in 
coagulation factors. However, some experiments 
indicated that melatonin affects fibrinolysis 
without affecting the coagulation process (6, 7). 
The effects of melatonin on platelets are also 
unclear. Melatonin may inhibit platelet aggregation 
by inhibiting arachidonic acid and thromboxane B2 
(8). Furthermore, an increment in platelet levels 
was observed after administering melatonin in 
patients with different causes of thrombocytopenia 
(9). Melatonin enhances calcium entry to the 
endothelial and subsequently stabilizes the 
endothelium (10). Thereby, clinical studies about 
the coagulant or anticoagulant effects of melatonin 
are inconsistent and inadequate; and more 
comprehensive and further investigations are still 
needed. 
It has been demonstrated that the administration 
of melatonin has beneficial neuroprotective effects 
in patients with hemorrhagic stroke in the 
intensive care unit (ICU) by improving clinical 
outcomes (11). Considering that hemorrhagic 
stroke patients are at higher risk for bleeding, there 
is a severe concern that the administration of 
higher doses of melatonin with a controversial 
coagulation profile may increase the risk of 
bleeding in these patients.  This study aimed to 
investigate the possible effects of high doses of 
melatonin on bleeding parameters and blood 
hemostasis.  
Methods 
Study design  
This randomized, double-blind, prospective, 
controlled trial evaluated the melatonin effect on 
coagulation following hemorrhagic stroke. It was 
carried out in the ICU of Sina hospital, Tehran, Iran. 
This clinical trial was registered by the Iranian 
Registry of Clinical Trials 
(IRCT201610225073N2). The ethical committee of 
Baqiyatallah University of Medical Sciences 
approved the study protocol (Ethics Code: 
IR.BMSU.REC.1395.89). Before enrollment, all 
patients’ companion was provided with verbal 
information and written consent. 
Study population 
To be eligible for enrollment, participants met the 
following inclusion criteria: patients admitted to 
the ICU within 72 hours of hemorrhagic stroke 
confirmed by computed tomography (CT) scan. 
Exclusion criteria were evidence of hepatic or renal 
failure, brain tumor, Glasgow Coma Scale (GCS) 
more than 8, known hypersensitivity to melatonin, 
and rheumatologic or autoimmune diseases. 
The sample size was estimated as 15 per group 
based on earlier experience and previous studies 
by using the sample size equation 
(N=(z1−α2⁄−z1−β) 2 (SD1+ SD2) 2/d2) for 
comparing two means (α=0.05; β=0.2) (12). The 
sample size was calculated based on the 
hemodynamic parameters, including prothrombin 
time (PT). The numbers replaced in the sample size 
equation were obtained through a pilot evaluation 
in the early stages of the study, which were all 
confirmed at the end. 
Randomization 
In this prospective study, double-blinded 
randomization was used. Thirty eligible patients 
were randomly enrolled in two groups using a 
permuted block randomization method. Blocks of 
four were used. Each patient was given a six-digit 
random number. Patients were allocated to the 
study group according to Random Number Table.  
Intervention 
Participants in the first group received 30 mg of 
melatonin (Melatonin tablets were purchased from 
Razak Company) daily via gastric tube gavage for 5 
days, while patients in the second group did not 
receive this medicine. Patients in each group 
received the standard treatment of care for 
hemorrhagic stroke. Each patient was monitored 
for 5 days, and 2 blood samples were taken. The 
first one was before melatonin administration, and 
the second sample was obtained 5 days later. Blood 
samples were centrifuged, and the serum was kept 
at -80 °C for later assessments. The principal 
investigator, who had no clinical involvement in 
the trial, performed randomization and blinding. 
Patients, clinical personnel, and investigator of 
clinical responses were all blind to the study's 
arms.  
Primary endpoints 
The study's primary outcome criteria were serum 
biomarkers, including D-dimer, fibrinogen level, 
platelet count, PT, partial thromboplastin time 
(PTT), international normalized ratio (INR), von 
Willebrand factor (vWF), and factor VIIa. The 
serum levels of biomarkers were measured at 
baseline and five days after melatonin initiation.  
Secondary endpoints 
Secondary outcome criteria were age, mortality, 
length of ICU stay, and level of consciousness. Rate 
of mortality was evaluated by using Acute 
Physiology and Chronic Health Evaluation II 
(APACHE-II) criteria. Level of consciousness was 
measured by Glasgow Coma Scale (GCS). 
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Furthermore, lab data of patients, including blood 
urea nitrogen (BUN), serum creatinine (Cr), white 
blood cell (WBC), and hemoglobin (Hb) were 
recorded at baseline and then on day 5. 
Statistical analysis  
Descriptive baseline characteristics for the two 
groups comparisons were tabulated as mean ± SD, 
or as percentages. If the data distribution was 
normal, the parametric test (sample T-test) was 
used. If data distribution was not normal, non-
parametric tests (Mann-Whitney test and Wilcoxon 
Test) were used. Since the comparison was before 
and after and we wanted to calculate the difference 
between the findings, in the comparison of before 
and after in each group, Wilcoxon Test was used. 
All statistical analysis was conducted using SPSS 
software version 16 and differences with a value of 
p< 0.05 were considered to be significant. Analysis 
was performed on an intention-to-treat basis. 
RESULTS 
Participants  
The enrollment flow chart of the patients was 
displayed in figure 1.  In total, 30 patients were 
randomly assigned to melatonin (n=15) or control 
groups (n=15). Demographic and baseline clinical 
characteristics of patients were presented in Table 
1. As indicated, there was no significant difference 
between the two groups in demographic and 
clinical characteristics (age, gender, body mass 
index, urea, Ca, Na, K and the sequential organ 
failure assessment score). 
Values of coagulation and blood parameters in 
melatonin and control groups before and after the 
intervention are reported in table 2. A significant 
rise in platelet count followed the intervention in 
the melatonin and control groups was observed 
(p<0.05), increasing from 167.33±51.2 × 109/L 
before administration of melatonin to 243.00±41.4 
× 109/L at the end of study period (p=0.005). The 
same trend was followed for the control group, 
increasing from 173.73±65.8 × 109/L to 
208.26±34.8 × 109/L after intervention (p=0.008). 
The mean difference for melatonin was much 
higher (75.66 vs 34.53), but the difference between 
the two groups was not statistically significant 
(p=0.206). There was a significant reduction in the 
PT in the melatonin group after the intervention, 
decreasing from 16.30±2.6 seconds to 14.98±2.2 
seconds (p=0.021). Moreover, by comparing the 
mean of PT decrement between the two groups, the 
melatonin group had a significant decrease during 
 
Figure 1: Flow diagram of the study 
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study period, based on the Mann–Whitney 
test (p=0.011). There were no significant changes 
in the level of other blood parameters like PTT, 
PTT-Ratio, Hb, INR, white blood cell (WBC), and 
hematocrit (HCT). Furthermore, we observed no 
statistical differences in these parameters within 
the study period between the melatonin and 
control groups (p>0.05). 
Comparison of fibrinogen, D dimer, factor VII, vWB 
factor levels in melatonin and control groups 
before and after the intervention are reported in 
table 3. Based on the Wilcoxon test, there was a 
significant difference in fibrinogen level in the 
melatonin and control groups after the 
intervention. Before intervention, fibrinogen level 
was 459.9±73.9 mg/dL which changed to 
380.9±71.9 mg/dL at the end of study. Based on the 
Mann-Whitney U test, the melatonin group had a 
statistically significant reduction in fibrinogen 
levels (p=0.0001). Based on the Wilcoxon test, p-
values for factor VII and vWB factor suggested a 
significant increment in these two factors in the 
melatonin group after the intervention (p=0.035 & 
p=0.002, respectively). However, there was no 
significant change in the control group. Overall, 
taking melatonin, compared with the control, 
significantly increased factor VII and vWB factor, 
increasing from 116.3±34.3 µg/dL to 122.7±35.5 
µg/dL for factor VII, and from 101.8±25.2 IU/dL to 
113.7±21.8 IU/dL for vWB factor (p=0.858 & 







0.329 52.9±13.7 57.7±12.7 Age (year) 
0.232 9 (60) 12 (80) Sex (male) 
0.05 24.6±1.79 26.03±1.84 BMI (kg/m2) 
0.215 25.7±9.27 33.9±14.1 Urea (mg/dl) 
0.324 8.94±0.23 9.29±0.85 Ca (mg/dl) 
0.132 141.8±5.24 146.1±5.02 Na (mEq/l) 
0.220 4.18±0.31 4.01±0.20 K (mEq/l) 
0.228 6.64±0.93 6.27±0.70 SOFA score 
BMI: body mass index; Ca: calcium; Na: sodium; K: potassium; SOFA score: The Sequential Organ Failure Assessment (SOFA) score. 
Numerical values were reported as mean±SD and nominal values as n(%). Student’s t-test and Chi-square were used to compare these 
values, respectively. 
 
Table 2: Values of coagulation and blood parameters in melatonin and control groups before and after the intervention 
Variable 
Melatonin Group Control Group 







diff Mean±SD Mean±SD 
PLT (×109/L) 167.33±51.2 243.00±41.4 0.005# 75.66 173.73±65.8 208.26±34.8 0.008# 34.53 0.206 
PT (sec) 16.30±2.6 14.98±2.2 0.021# -1.32 14.70±1.04 14.71±1.1 0.317 0.01 0.011# 
PTT (sec) 36.07±4.6 35.60±5.1 0.729 -0.47 35.93±5.2 37.07±2.9 0.348 1.13 0.419 
PTT-R 1.267±0.27 1.25±0.08 0.613 -0.02 1.28±0.28 1.20±0.13 0.717 -0.09 0.513 
Hb (mg/dL) 11.89±4.5 10.83±1.7 0.348 -1.07 10.56±2.8 10.52±1.7 0.589 -0.05 0.262 
INR 1.29±0.32 1.22±0.14 0.691 -0.07 1.329±0.29 1.21±0.17 0.088 -0.12 0.361 
WBC (x109/L) 10.08±2.2 10.29±3.9 0.820 0.22 9.13±2.7 9.13±2.7 0.977 -0.006 0.575 
HCT (%) 32.45±7.2 31.19±5.7 0.410 -1.26 34.53±7.8 34.53±5.5 0.955 0.00001 0.604 
PLT: platelet; PT: prothrombin time; PTT: partial thromboplastin time; PTT-R: PTT-Ratio; Hb: hemoglobin; INR: international 
normalized ratio; WBC: white blood cell; HCT: hematocrit. 
* Based on Wilcoxon test; ^ Based on Mann–Whitney test; # significant difference 
 
Table 3: Comparison of fibrinogen, D dimer, factor VII, VWB factor levels in melatonin and control groups before and after the 
intervention 
Variable 
Melatonin Group Control Group 







diff Mean±SD Mean±SD 
Fibrinogen 
(mg/dL) 
459.9±73.9 380.9±71.9 0.001# -79.06 432.1±57.9 467.9±61.9 0.025# 35.80 0.0001# 
D-dimmer 
(ng/mL) 
3180.1±1614.1 2986.8±1195.6 0.100# -193.93 3087.9±1298.5 2957.8±1143.2 0.061 -130.0 0.787 
Factor VII 
(IU/dL) 
116.3±34.3 122.7±35.5 0.035 6.46 126.5±33.1 126.5±33.4 0.858 -0.06 0.043# 
vWB factor 
(IU/dL) 
101.8±25.2 113.7±21.8 0.002 11.93 88.4±33.4 93.3±29.3 0.107 4.93 0.043# 
vWB: von Willebrand factor  
* Based on Wilcoxon test; ^ Based on Mann–Whitney test; # significant difference 
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p=0.107, respectively). D-dimer factor showed no 
significant change after intervention in both arms, 
and there was no significant difference between 
the two groups either (p=0.787). 
Comparison of GCS, APACHE-II, and renal indices in 
melatonin and control groups before and after the 
intervention are provided in table 4. No significant 
changes in APACHE II and GCS parameters were 
evident in both groups after the intervention, and 
no significant differences were observed in the 
comparison of the melatonin group and the control 
group (p>0.05). Regarding the BUN and creatinine 
parameters, although there was a significant 
increment in both groups during the study period, 
no differences were found between melatonin and 
control groups.  
Comparison of mechanical ventilation rate, length 
of hospitalization, mortality rate, and infection are 
presented in table 5. The length of ICU stay in the 
melatonin group was significantly shorter than the 
control group, 8 (6-21) days for melatonin group 
and 12 (8-25) days for (p=0.041). Although 
mechanical ventilation was shorter in the 
melatonin group compared to the control group, 
there was no significant difference between the 
two groups (p=0.065). Similarly, the rate of 
mortality and infection was lower in melatonin-
consuming patients. However, it was not 
statistically significant (p>0.05).  
DISCUSSION 
In recent years, melatonin's advantageous effects 
in reducing the complications following stroke and 
hypoxia have been proven (13, 14). Melatonin 
stabilizes endothelial and regulates vascular tone 
by its impact on the endothelium calcium signaling 
pathway. This agent improves calcium 
mobilization and its entrance to endothelial cells 
(10). Moreover, it has been shown that melatonin 
was able to decrease proinflammatory cytokines 
(15).  
A study carried out by Dianatkhah et al. confirmed 
the beneficial neuroprotective effects of 30 mg of 
melatonin in patients with hemorrhagic stroke in 
the intensive care unit (11). Since hemorrhagic 
stroke patients are at higher risk for the occurrence 
of bleeding, we decided to evaluate the possible 
effects of high doses of melatonin on blood 
hemostasis in this group of patients. The results of 
melatonin on hemostasis are poorly studied, and 
published reports are also contradictory. The 
current study documented a significant increase in 
platelet count after the intervention in melatonin 
and control groups.  
However, the difference was not statistically 
significant. In agreement with our study, Irina 
Pashalieva et al. found that melatonin, as an 
essential regulator of thrombocyte homeostasis in 
rats, can cause a significant elevation in 
thrombocyte count and markers of functional 
activity of thrombocytes, known as beta-
thromboglobulin (β-TG) and platelet factor 4 (PF-
4) (16). 
Melatonin is a lipophilic molecule that readily 
crosses the cell membrane. The increase in platelet 
count can be due to the effects of melatonin on bone 
marrow cells. Furthermore, the impact of 
melatonin on platelets can be related to platelet 
production cytokines (17). In a study by Lissoni et 
al., 200 patients with various causes of 
 
Table 4: Comparison of GCS, APACHE-II, and renal indices in melatonin and control groups before and after the intervention 
Variable 
Melatonin Group Control Group 
Before After 
P* Mean diff 
Before After 
P* Mean diff P* 
Mean±SD Mean±SD 
GCS 6.5±2.7 7.5±2.8 0.142 0.93 7.6±3.2 7.73±2.89 0.972 35.80 0.235 
APACHE-II 19.5±9.4 18.7±7.4 0.189 -0.73 19.7±7.6 17.80±7.33 0.067 -130.0 0.833 
BUN 39.7±15.6 42.9±17.9 0.211 3.27 34.5±13.47 39.53±10.39 0.023# -0.06 0.618 
Cr 1.1±0.5 1.4±0.77 0.027# 11.93 0.97±0.33 1.12±0.302 0.035# 4.93 0.442 
GCS: Glasgow Coma Scale; BUN: blood urea nitrogen; Cr: creatinine 
* Based on Wilcoxon test; # significant difference 
 
Table 5: Comparison of mechanical ventilation rate, length of hospitalization, mortality rate, and infection 
P-Value Control Melatonin Variable 
0.065 12 (4-20) 4 (2-16) Duration of mechanical ventilation (Days) 
0.041* 12 (8-25) 8 (6-21) Length of ICU stay (Days) 
0.451 6 (30.0) 3 (15.0) In ICU mortality 
0.095 10 (50.0) 5 (25.0) Sepsis 
Numerical values were reported as median (Interquartile range), and nominal factors as number (%), Mann-Whitney U test and fisher 
exact test were used to compare these values. 
* significant difference 
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thrombocytopenia, 20 mg/day of melatonin were 
given orally for a month. Finally, 72% of patients 
experienced a rapid increment in mean platelet 
number, and no melatonin-related toxicity was 
reported in any of the patients. This study 
suggested that melatonin could stimulate platelet 
generation by modulating the cytokines involved in 
platelet production and promoting the 
fragmentation of the megakaryocytes (9). In 
another study performed on 5 individuals, 
melatonin inhibited the platelet activation induced 
by collagen and arachidonic acid. Furthermore, 
melatonin inhibits platelet function in the 
cyclooxygenase-dependent pathway. Besides, it 
has been proposed that the cyclooxygenase 
pathway involves platelet aggregation induced by 
melatonin, too (8). 
Contrary to previous studies mentioned, in an in-
vitro study by Kesturu Subbaiah Girish et al., 
melatonin enhanced apoptosis in platelets by 
releasing free radicals, particularly H2O2 (18). A 
significantly shortened PT in the melatonin group 
was observed in the current study, suggesting that 
this hormone has pro-coagulant properties. The 
results of an animal study performed on 52 male 
Wistar rats provided strong evidence that 
melatonin significantly shortened the activated 
partial thromboplastin time (aPTT), PT, and 
thrombin time. Indeed, melatonin promoted a 
tendency to hypercoagulability by activating the 
coagulation pathways and the conversion of 
fibrinogen to fibrin (19). Bekyarova et al. evaluated 
the effects of melatonin on burn-induced 
inflammatory responses and coagulation disorders 
in rats. Melatonin diminished the elevated c-
reactive protein (CRP) and fibrinogen levels, 
normalized malondialdehyde levels, platelet 
morphology, and decreased prothrombin 
activity in rats with burn injury. Thus, melatonin 
acted as an anticoagulant substance (20).  
Tugba Tunali et al. demonstrated that melatonin 
reduced oxidative damage to the skin and 
normalized blood coagulation induced by thermal 
injury. Melatonin limited the entrance of tissue 
factors to the bloodstream by reduction of skin 
oxidant damage. Intraperitoneal injection of 
melatonin to the thermal injury rat models caused 
PT normalization and fibrin degradation products 
(FDPs) decrement (21). In our study, plasma levels 
of fibrinogen decreased in the melatonin group 
after the intervention, which indicated the 
antithrombotic effect of melatonin.  
A placebo-controlled human survey by Petra H. 
Wirtz and colleagues in 2008 showed that oral 
administration of melatonin was associated with 
decreased plasma levels of factor VIII and 
fibrinogen, while factor VII and D-Dimer did not 
change. Parallel with our findings, such decrement 
in coagulation factors indicated the antithrombotic 
effect of melatonin. There is probably a dose-
response relationship between the plasma 
concentration of melatonin and coagulation 
activity (6). In another human study conducted by 
Wirtz et al. the effect of melatonin on stress-
induced pro-coagulant response was investigated. 
Consequently, it demonstrated that melatonin 
reduced D-dimer plasma levels without affecting 
the VII, VIII and fibrinogen factors. Additionally, it 
concluded that melatonin did not affect the 
coagulation process but affected the following 
stage, fibrinolysis (7). Yuri Nyagolov et al. reported 
that melatonin shortened aPTT, increased factors 
V, XII, and XIII but did not affect factor XI. Thus, the 
melatonin application was accompanied by a 
tendency to hypercoagulability (22). Recent 
studies in COVID-19 patients indicate that the viral-
induced systemic inflammatory responses trigger 
endothelial dysfunction, the waterfall coagulation 
cascade, and subsequent stroke and MI (23, 24). 
Thereby, melatonin's anti-inflammatory and 
endothelial stabilizing properties make this 
supplement a potential adjuvant in stroke with a 
favorable safety profile. 
We observed a significant rise in vWF plasma levels 
in the melatonin group compared to the control 
group. Negrin Negrev and colleagues indicated that 
melatonin could increase the Tissue Factor and 
vWF factor and simultaneously reduced the level of 
tissue factor pathway inhibitor (TFPI). TF is 
involved in the external coagulation pathway via 
binding to the factor VIIa. TFPI blocks the external 
coagulation pathway by inhibiting TF.  vWF also 
plays a significant role in the coagulation process 
by helping attach platelets to endothelium and 
inhibiting factor VIII proteolysis. Therefore, 
melatonin's mentioned effects on TF, TFPI, and 
vWF show that melatonin induces a pronounced 
tendency to hypercoagulability in rats (25). 
Furthermore, in agreement with the previous 
study, Emiliya Stancheva et al. showed that 
melatonin lowered the plasma levels of protein C, 
protein S, and thrombomodulin, which involves the 
anticoagulant pathway. Inhibition of anticoagulant 
factors can be considered one of the mechanisms 
by which this neurohormone causes an evident 
tendency to hypercoagulability (26).  
Limitations 
The major limitation of the present study was the 
small number of patients. Although the results of 
this study showed positive effects of melatonin in 
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hemorrhagic stroke with acceptable coagulation 
safety, but due to the small sample size, the results 
of this study should be confirmed in a large clinical 
trial with predefined outcomes.  
CONCLUSIONS 
The significant increase in platelet level, reduction 
in prothrombin time, and VWF and VII factors in 
the melatonin group indicates its pro-coagulant 
properties. The statistically significant decrease in 
fibrin levels is suggestive of its anti-thrombin 
effects of melatonin. Further studies with a larger 
sample size could help make a conclusive decision 
to administer melatonin in intensive care patients 
with hemorrhagic stroke. 
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